Home
overview
Diabetes is a major global health problem, which currently effects more than 140 million people worldwide. The numbers are increasing such that the World Health Organisation (WHO) has predicted that over the next 25 years the number of people with diabetes will reach 300 million. In fact, diabetes has become the only non-infectious disease that WHO has designated as an epidemic.

Diabetes is a chronic disease and unless it is properly treated it can result in severe complications including kidney failure, blindness, cardiovascular problems, neurological conditions and death.

Diabetes 2000 will consider type 1 and type 2 diabetes and will look at developments in anti-diabetic drugs, potential drugs of the future and advances in the genetics of diabetes. This conference aims to provide a thorough understanding of the issues and developments surrounding this major disease by bringing together experts in the field and combining their knowledge with the objective of making major advances in the treatment of diabetes.

As a senior industry executive, you will be aware of the importance and potential of this field. I would therefore like to invite you to register for SMi’s Diabetes 2000 conference. As you will see from the brochure, key speakers include experts from leading international pharmaceutical and biotech companies.

Please register now to guarantee your place at this important conference.

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Dr Richard Palmer

Dr Richard Palmer, Chief Executive Officer, Alizyme

9:10 DIABETES: AN OVERVIEW

Larry K Ellingson

Larry K Ellingson, Executive Director, Global Diabetes Care, Eli Lilly

  • Prevalence of diabetes
  • Epidemiology of diabetes
  • Economic impact of diabetes
  • Understanding the limitations of current therapeutic options
  • Unmet needs of diabetes
  • Future therapies: working toward treating the underlying disease pathology
  • 9:40 GLITAZONES: GLYCAEMIC CONTROL IS ONLY THE BEGINNING

    Dr Murray Stewart

    Dr Murray Stewart, Assistant Director, Clinical Research & Development, Medical Affairs UK, SmithKline Beecham

  • About glitazones or thiazolidinediones
  • Targeting diabetes
  • Evaluating risks and benefits
  • Effect on metabolic syndrome
  • Future of glitazones
  • 10:20 PREVENTING THE ONSET OF TYPE 1 DIABETES

    Dr Nanette Solvason

    Dr Nanette Solvason, Senior Scientist, Corixa

  • Addressing type 1 diabetes with two clinical stage platforms
  • Interfering with the activation of disease specific auto-relative T-cells
  • AnervaX.DB™: therapeutic MHC-derived peptide vaccine
  • Genetic susceptibility to diabetes and the design of the AnervaX molecule
  • Mapping diabetes type 1 susceptibility onto an MHC region
    Using AnervaX to down-regulate the MHC region in type 1 diabetes
  • AnervaX.DB™: its potential as a vaccine for treating and preventing the onset of type 1 diabetes
  • 11:00 Morning Coffee

    11:20 LEADS FROM NATURAL EXTRACTS FOR TREATING DIABETES

    Dr Bishwajit Nag

    Dr Bishwajit Nag, Chief Scientific Officer, Vice President, Research & Development, Calyx Therapeutics

  • Isolating compounds for treating diabetes
  • Evaluating compounds for treating type I and type II diabetes
  • CLX-0101: novel peptide for the treatment of diabetes
  • CLX-0901: from discovery to clinical trials - how CLX-0901 is different from other anti-diabetic compounds
  • CLX-0921: a new TZD analogue of CLX-0901: toward clinical development
  • 12:00 A.G.E. FORMATION INHIBITORS AND PIMAGEDINE

    Dr John Egan

    Dr John Egan, Executive Director, Licensing & Technology, Alteon

  • The role of Advanced Glycosylation End-Products (A.G.E.) crosslinks in the development in diabetes nephropathy
  • Proteinuria as a direct marker for damage to glomerular basement membrane
  • Pimagedine: inhibiting the formation of A.G.Es
  • Mechanism of action
  • Other indications of pimagedine in diabetic complications
  • Benefits to patients of pimagedine
  • 12:40 Networking Lunch

    14:00 NOVEL AGENTS FOR THE TREATMENT OF EARLY AND LATE STAGE DIABETES

    Dr Andreas Sommer

    Dr Andreas Sommer, Principal Scientist, Insmed

  • INS-1: a naturally occurring insulin sensitiser fro early treatment of diabetes
  • INS-1: biology and rationale
  • INS-1: metabolic effects and safety. Review of clinical data
  • SomatoKine: a therapeutic IGF-1 composition for late stage treatment of diabetes
  • Somatokine® : biology and rationale
  • Somatokine® : metabolic effects and safety. Review of clinical data
  • 14:40 ADDRESSING THE LONG TERM DEGENERATIVE CHANGES IN DIABETICS

    Dr Laszlo Koranyi

    Dr Laszlo Koranyi, Medical Director, Biorex R&D

  • Preventing pathological changes in diabetics
  • The role of Heat Shock Proteins (HSP) in diabetes
  • Co-inducing HSPs using Bimoclomol
  • Mechanism of action of Bimoclomol
  • Continuing research into the Bimoclomol compound
  • Identifying more potent and specific second generation molecules for the treatment of diabetic complications
  • 15:20 Afternoon Tea

    15:40 THE USE OF NOVEL PEPTIDES IN THE MANAGEMENT OF DIABETES

    Dr Orville G Kolterman

    Dr Orville G Kolterman, Senior Vice President, Clinical Affairs, Amylin Pharmaceuticals

  • Understanding the benefits of novel peptides in treating people with diabetes
  • Developing two anti-diabetic compounds
  • Phase 3 clinical trials in diabetic patients: the SYMLIN™ phase 3 programme
  • Mechanism of action of SYMLIN™
  • AC2993: synthetic exendin-4
  • Mechanism of action
  • 16:20 FOCUSING ON DIABETES

    Thomas A Glaze

    Thomas A Glaze, President & Chief Executive Officer, Metabolex

  • Fundamental role of biology in research
  • Genomics leveraging biology for target discovery
  • Drug development candidates
  • Partnering strategy
  • M&A strategy
  • Financial market perspectives
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    17:10 Networking drinks reception

    8:30 Re-registration & Coffee

    9:00 Chairman's Opening Remarks

    Dr Bruce Zimmerman

    Dr Bruce Zimmerman, Consultant, Endocrinology, Past President of the American Diabetes Association, Mayo Clinic

    9:10 PURSUING RESEARCH INTO DIABETES

    Malcolm Allison

    Malcolm Allison, Global Brand Director, Novartis AG

  • Working on adult onset diabetes
  • Offering advances in the treatment of diabetes
  • Differentiating from existing treatments
  • Improving disease control
  • Mechanism of action of Starlix®
  • 9:40 IMPROVING DIABETES THERAPY

    Dr Peter Kurtzhals

    Dr Peter Kurtzhals, Director of Discovery Biology, R&D, Novo Nordisk

  • The aim of insulin replacement therapy
  • Engineering human insulin analogues
  • Monitoring the toxico-pharmacological properties of insulin analogues
  • Evaluating receptor binding properties and metabolic and mitogenic potencies
  • Clinical profile of human insulin analogues
  • 10:20 MAPPING TYPE 2 DIABETES GENES IN THE UK DIABETES GENETICS CONSORTIUM

    Dr Mark McCarthy

    Dr Mark McCarthy, Reader in Molecular Genetics, Imperial College

  • Identifying and validating susceptibility regions for type 2 diabetes
  • Rational selection of positional candidates: triangulating on positional and functional information
  • How will we know when we have a susceptibility variant?
  • Case studies: UCP3; insulin; NIDDM1
  • The hopes and challenges of molecular epidemiology
  • 11:00 Morning Coffee

    11:20 HUNTING FOR TYPE 2 DIABETES GENES

    Dr Simon Bennett

    Dr Simon Bennett, Programme Manager, Oxagen

  • Genetic basis of type 2 diabetes
  • Strategies for dissecting the genetic component
  • Integrated clinical genetics approach for gene targeting
  • Linkage disequilibrium mapping in an isolated population
  • The post-genomics era
  • 12:00 GENES, SNPs AND DIABETES

    Dr Alan Schafer

    Dr Alan Schafer, Vice President, Genetics, Incyte Genomics

  • Identifying candidate genes associated with diabetes
  • Identifying novel disease pathways and validating drug targets for diabetes
  • Identifying key genes responsible for type 2 diabetes
  • Using SNP discovery technology to discover DNA variations in genes involved in diabetes
  • PPARg: coding for a protein targeted by thiazolidinediones
  • Discovering mutations in the PPARg gene
  • 12:40 Networking Lunch

    13:40 FUTURE THERAPEUTIC OPTIONS

    Dr Mike Rothe

    Dr Mike Rothe, Chief Scientific Officer, and Dr Edward Stuart, Chief Operating Officer, DeveloGen

  • Regenerating missing beta cells
  • Searching for stem cells
  • Identifying developmental control genes
  • Involvement of the PAX gene family
  • Using development control genes in diabetes treatment
  • 14:20 TAKE A DEEP BREATH!

    Dr Andreas Pfützner

    Dr Andreas Pfützner, President & Medical Director, IKFE

  • Current approaches to pulmonary insulin developments
  • Challenges and solutions
  • Pharmacokinetic and pharmacodynamic aspects
  • Clinical results
  • Questions to be solved
  • 15:00 DPIV-INHIBITION FOR MANAGING NIDDM

    Dr Hans-Ulrich Demuth

    Dr Hans-Ulrich Demuth, Chief Executive Officer, Chief Scientific Officer, Probiodrug

  • What is DPIV?
  • DPIV-inhibitors in animal studies
  • DPIV-inhibitors in human studies
  • 15:40 Afternoon Tea

    16:00 NOVEL INSULIN DELIVERY DEVICES

    Scott R King

    Scott R King, President, Islet Sheet Medical

  • Means for attaining risk-free euglycemia
  • Implantation of islets of Langerhans
  • The ‘Edmonton Protocol’
  • Design objectives for the bio-artificial pancreas
  • Results in studies of diabetic large animals
  • Regulatory issues
  • 16:30 PROTEOMICS AS A TOOL FOR NEW MOLECULAR TARGET IDENTIFICATION

    Prof Michael Cawthorne

    Prof Michael Cawthorne, Director of Metabolic Research, Proteome Sciences

  • Future therapeutic strategies for type 2 diabetes
  • Islet cell regeneration/protection and insulin sensitivity/second messenger targets
  • Identifying model systems
  • Technology challenges
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.